Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the counteracting effects of hepatoprotective agents

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 796-802

  Xie, Yuan ^a   Wang, Guangji ^a   Wang, Hong ^a   Yao, Xilin ^a   Jiang, Shan ^a   Kang, An ^a   Zhou, Fang ^a   Xie, Tong ^a   Hao, Haiping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A10; CYTOCHROME P450 3A11; CYTOCHROME P450 3A12; CYTOCHROME P450 3A13; CYTOCHROME P450 3A14; CYTOCHROME P450 3A15; CYTOCHROME P450 3A16; CYTOCHROME P450 3A17; CYTOCHROME P450 3A18; CYTOCHROME P450 3A2; CYTOCHROME P450 3A3; CYTOCHROME P450 3A30; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A6; CYTOCHROME P450 3A7; CYTOCHROME P450 3A71; CYTOCHROME P450 3A8; CYTOCHROME P450 3A9; DIPHENYL DICARBOXYLATE; LIGNAN DERIVATIVE; LIVER PROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCHISANDRA CHINENSIS EXTRACT; THIOACETAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME DEFECT; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME REGULATION; LIVER CIRRHOSIS; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; LIGNANS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TESTS; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; PLANT EXTRACTS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SCHISANDRA; STEROID 21-HYDROXYLASE; THIOACETAMIDE; TIME FACTORS;

RATTUS; SCHISANDRA;

EID: 84863337739     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043539     Document Type: Article

References (21)

1. Avni Y, Shirin H, Aeed H, Matas Z, Shahmurov M, Birkenfeld S, and Bruck R (2003) Thioacetamide-induced hepatic damage in a rat nutritional model of steatohepatitis. J Med 34:121-137. (Pubitemid 47457279)
2. Brady JF, Dokko J, Di Stefano EW, and Cho AK (1987) Mechanism-based inhibition of cytochrome P-450 by heterocyclic analogues of phencyclidine. Drug Metab Dispos 15:648-652. (Pubitemid 18004620)
3. Camus-Randon AM, Raffalli F, Béréziat JC, McGregor D, Konstandi M, and Lang MA (1996) Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol Appl Pharmacol 138:140-148. (Pubitemid 26159604)
4. Chieli E and Malvaldi G (1984) Role of the microsomal FAD-containing monooxygenase in the liver toxicity of thioacetamide S-oxide. Toxicology 31:41-52. (Pubitemid 14120881)
5. Hao H, Zhang L, Jiang S, Sun S, Gong P, Xie Y, Zhou X, and Wang G (2011) Thioacetamide intoxication triggers transcriptional up-regulation but enzyme inactivation of UDP-glucuronosyltransferases. Drug Metab Dispos 39:1815-1822.
6. Hunter AL, Holscher MA, and Neal RA (1977) Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 200:439-448. (Pubitemid 8037503)
7. Ishikawa S, Ikejima K, Yamagata H, Aoyama T, Kon K, Arai K, Takeda K, and Watanabe S (2011) S CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol 54:1195-1204.
8. Kamataki T and Kitagawa H (1974) Effects of EDTA on stability of drug metabolizing enzymes in liver microsomes of rats. Chem Pharm Bull (Tokyo) 22:1041-1045.
9. Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, and Fukushima S (2008) Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol Appl Pharmacol 228:295-300.
10. Kaul KL and Novak RF (1987) Inhibition and induction of rabbit liver microsomal cytochrome P-450 by pyridine. J Pharmacol Exp Ther 243:384-390. (Pubitemid 17162744)
11. Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, et al. (2009) Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 37:2399-2407.
12. Ledda-Columbano GM, Coni P, Curto M, Giacomini L, Faa G, Oliverio S, Piacentini M, and Columbano A (1991) Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am J Pathol 139:1099-1109.
13. Li X, He Y, Ruiz CH, Koenig M, Cameron MD, and Vojkovsky T (2009) Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 37:1242-1250.
14. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
15. Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, et al. (2006) Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 316:1369-1377. (Pubitemid 43345314)
16. Nakajima M, Iwata K, Yamamoto T, Funae Y, Yoshida T, and Kuroiwa Y (1998) Nicotine metabolism in liver microsomes from rats with acute hepatitis or cirrhosis. Drug Metab Dispos 26:36-41. (Pubitemid 28071322)
17. Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, Ai H, and Wang G (2008) Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36:1308-1314. (Pubitemid 351929315)
18. Steib CJ, Hennenberg M, Beitinger F, Hartmann AC, Bystron M, De Toni EN, and Gerbes AL (2010) Amiloride reduces portal hypertension in rat liver cirrhosis. Gut 59:827-836.
19. Xie Y, Hao H, Kang A, Liang Y, Xie T, Sun S, Dai C, Zheng X, Xie L, Li J, et al. (2010) Integral pharmacokinetics of multiple lignan components in normal, CCl4-induced hepatic injury and hepatoprotective agents pretreated rats and correlations with hepatic injury biomarkers. J Ethnopharmacol 131:290-299.
20. Yeh TS, Ho YP, Huang SF, Yeh JN, Jan YY, and Chen MF (2004) Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats. J Hepatol 41:606-612.
21. Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Bornemann J, Kowalska MA, Gassler N, Streetz KL, Weiskirchen R, et al. (2010) CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 51:1345-1353.